Medicines List

Description

Co-Telsart is a combination of an angiotensin II receptor antagonist, telmisartan, and a thiazide diuretic – hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect which reduces blood pressure to a greater degree than either component alone. When received once daily within the therapeutic dosage range, Co-Telsart produces effective and smooth reduction in blood pressure.

Indications

Co-Telsart 80 mg/12.5 mg tablets
– treatment of essential hypertension;
– Co-Telsart fixed-dose combination (80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.

Co-Telsart 80 mg/25 mg tablets
– treatment of essential hypertension;
– Co-Telsart fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Co-Telsart 80 mg/12.5 mg (80 mg Telmisartan/12.5 mg hydrochlorothiazide) or adults who have previously stabilized on Telmisartan and hydrochlorothiazide given separately.

Subject to medical prescription.

Concentration and pharmaceutical form: 80 mg/12.5 mg; 80 mg/25 mg tablets

Patient information leaflet

Description

Cordacare Plus is a fixed-dose combination product containing lisinopril, an inhibitor of angiotensin converting enzyme (ACE) and hydrochlorothiazide, a thiazide diuretic. Lisinopril works by making blood vessels widen. Hydrochlorothiazide helps get rid of water and salts, such as sodium, in urine.

Indications

Fixed-dose combination Cordacare Plus (10 mg or 20 mg lisinopril and 12.5 mg hydrochlorothiazide) is indicated for the treatment of mild to moderate hypertension in patients who have been stabilised on the individual components given in the same proportions.

Subject to medical prescription.

Concentration and pharmaceutical form: 10 mg/12.5 mg, 20 mg/12.5 mg tablets

Description

Amarhyton is a Class IC antiarrhythmic agent used in the treatment of severe symptomatic life-threatening ventricular arrhythmias and supraventricular arrhythmias.

Indications

Amarhyton is used for treatment of:
– AV nodal reciprocating tachycardia; arrhythmias associated with Wolff-Parkinson-White Syndrome and similar conditions with accessory pathways, when other treatment has been ineffective;
– Severe symptomatic and life-threatening paroxysmal ventricular arrhythmia which has failed to respond to other forms of therapy. Also where other treatments have not been tolerated;
– Paroxysmal atrial arrhythmias (atrial fibrillation, atrial flutter and atrial tachycardia) in patients with disabling symptoms after conversion provided that there is definite need for treatment on the basis of severity of clinical symptoms, when other treatment has been ineffective. Structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk for pro-arrhythmic effects.

Subject to medical prescription.

Concentration and pharmaceutical form: 50 mg; 100 mg; 150 mg prolonged-release capsules, hard

Description

Pizona contains pioglitazone.
Pizona helps controlling the level of sugar in your blood when you have type 2 diabetes by helping your body make better use of the insulin it produces.

Indications

Pioglitazone is indicated for treatment of type 2 diabetes mellitus.

as monotherapy:
– in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.

as dual oral therapyin combination with:
– metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;
– a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea.

as triple oral therapyin combination with:
– metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.

Subject to medical prescription.

Concentration and pharmaceutical form: 15 mg, 30 mg, 45 mg tablets